- Detail
- Parameters
- Review
Lasmiditan succinate COL-144 LY573144 Lasmiditan hemisuccinate 439239-92-6
Lasmiditan succinate (COL-144, LY573144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (Ki=2.21 nM) without vasoconstrictor activity.
| Cas No. | 439239-92-6 |
Synonyms | COL-144, LY573144 |
Formula | C42H42F6N6O8 |
M.Wt | 872.81 |
Solubility | DMSO: 100 mg/mL (114.57 mM);Water: 14 mg/mL (16.04 mM);Ethanol: 9 mg/mL (10.31 mM) |
Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month. |
| To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Lasmiditan shows higher selectivity for the 5-HT(1F) receptor relative to other 5-HT(1) receptor subtypes than the first generation 5-HT(1F) receptor agonist LY334370[1].
Lasmiditan is orally active in two in vivo models of migraine that involve electrical stimulation of the trigeminal ganglion. After oral administration, lasmiditan potently decreases dural plasma protein extravasation and the number of c-fos positive cells in the trigeminal nucleus caudalis at a dose of 3 mg/kg[1].
References:
[1] Nelson DL, et al. Cephalalgia. 2010, 30(10):1159-69.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.